{
 "@context": "https://clearank.com/llms.txt",
 "@type": "clearank:AssetAnalysis",
 "url": "https://clearank.com/stock/elv-stock-analysis/",
 "dataUrl": "https://clearank.com/stock/elv-stock-analysis/data.json",
 "title": "Elevance Health (ELV) Stock Forecast & Price Target (2026)",
 "description": "Elevance Health, Inc. (ELV) stock: Healthcare, Healthcare Plans. $92.0B market cap. AI rating, technicals, 2030 forecast and trade plans.",
 "headline": "Elevance Health, Inc. (ELV)",
 "published": "2026-07-10T09:21:03+00:00",
 "modified": "2026-09-15T15:51:58.062+00:00",
 "generated": "2026-09-16T12:02:14.609Z",
 "language": "en-US",
 "publisher": {
  "name": "CleaRank",
  "url": "https://clearank.com/"
 },
 "disclaimer": "Educational and informational only; not financial advice. AI-generated analysis reviewed by the CleaRank editorial team; prices delayed up to 15 minutes.",
 "asset": {
  "ticker": "ELV",
  "name": "Elevance Health, Inc.",
  "type": "Common Stock",
  "exchange": "NYSE",
  "currency": "USD",
  "sector": "Healthcare",
  "industry": "Healthcare Plans",
  "country": "United States",
  "website": "https://www.elevancehealth.com"
 },
 "quote": {
  "price": 419.17,
  "previousClose": 424.24,
  "change": -5.07,
  "changePercent": -1.2,
  "open": 422.47,
  "high": 423.38,
  "low": 415.64,
  "volume": 20552,
  "averageVolume": 1122415,
  "marketCap": 92004625420,
  "fiftyTwoWeekHigh": 436.23999,
  "fiftyTwoWeekLow": 274.84,
  "marketOpen": false,
  "asOf": "2026-09-15T15:51:58.000Z"
 },
 "statistics": {
  "pe": 18.763378,
  "eps": 22.61,
  "dividendYield": 0.016413388362716795,
  "beta": 0.696,
  "priceToSales": 0.45747504,
  "priceToBook": 2.0496073,
  "revenueTtm": 201113993216,
  "grossMargin": null,
  "returnOnEquity": 0.11133
 },
 "technicals": {
  "rsi": 61.77,
  "macd": 6.2,
  "sma50": 397.6,
  "sma200": 361.94,
  "rsiSignal": "Bullish",
  "trend": "Bullish",
  "pricePosition": "Bullish",
  "macdSignal": "Bullish",
  "rating": "Bullish"
 },
 "analysis": {
  "rating": "Buy",
  "score": 70,
  "consensus": "Buy",
  "fairValue": 457,
  "analystTarget": 457,
  "analystCount": 22,
  "wallStreetConsensus": "Buy",
  "generatedAt": "2026-09-15T15:51:58.000Z",
  "priceAtAnalysis": 419.17,
  "volatility": {
   "daily": 1.68,
   "risk": "standard"
  }
 },
 "tradePlan": {
  "bias": "Bullish",
  "conservativeEntry": 410.79,
  "aggressiveEntry": 419.17,
  "stopLoss": 398.46,
  "stopLossPercent": 3,
  "targets": [
   431.33,
   451.87,
   472.4
  ]
 },
 "projections": {
  "basis": "Monte Carlo simulation on historical return distribution, re-run daily; not price targets",
  "years": [
   {
    "year": 2027,
    "downside10th": 308.63,
    "base": 461.32,
    "upside90th": 689.56
   },
   {
    "year": 2028,
    "downside10th": 287.57,
    "base": 507.71,
    "upside90th": 896.38
   },
   {
    "year": 2029,
    "downside10th": 278.53,
    "base": 558.77,
    "upside90th": 1120.96
   },
   {
    "year": 2030,
    "downside10th": 275.24,
    "base": 614.96,
    "upside90th": 1373.98
   },
   {
    "year": 2031,
    "downside10th": 275.5,
    "base": 676.8,
    "upside90th": 1662.66
   },
   {
    "year": 2032,
    "downside10th": 278.28,
    "base": 744.86,
    "upside90th": 1993.77
   },
   {
    "year": 2033,
    "downside10th": 283.03,
    "base": 819.77,
    "upside90th": 2374.38
   },
   {
    "year": 2034,
    "downside10th": 289.44,
    "base": 902.2,
    "upside90th": 2812.24
   },
   {
    "year": 2035,
    "downside10th": 297.32,
    "base": 992.93,
    "upside90th": 3316.03
   },
   {
    "year": 2036,
    "downside10th": 306.55,
    "base": 1092.78,
    "upside90th": 3895.48
   }
  ]
 },
 "faqCount": 7,
 "sources": [
  "TwelveData",
  "Wall Street consensus"
 ],
 "sections": [
  {
   "id": "price",
   "title": "ELV Price Analysis"
  },
  {
   "id": "market-metrics",
   "title": "Market Metrics",
   "facts": {
    "Open": "$422.47",
    "Day Range": "$415.64 to $423.38",
    "Prev Close": "$424.24",
    "Volume": "20.6K",
    "52-Week Range": "$274.84 to $436.24",
    "Market Cap": "$92.00B"
   }
  },
  {
   "id": "peer-benchmarking",
   "title": "Peer Benchmarking",
   "text": [
    "Sector Position Analysis Trading at a notable discount to sector peers (-41%), which may indicate undervaluation or specific company headwinds."
   ]
  },
  {
   "id": "financials",
   "title": "ELV Financial Performance",
   "text": [
    "Analysis: In the last 5 quarters, ELV beat estimates 5 times. However, the stock fell 3 times the next day. This suggests positive news is often \"priced in\" or investors are selling the news."
   ]
  },
  {
   "id": "analysis",
   "title": "ELV Analysis",
   "text": [
    "Elevance Health, Inc. (ELV) is currently trading above its 50-day SMA of $397.60 and its 200-day SMA of $361.94, indicating a bullish trend. The RSI is at 61.77, signaling bullish momentum, and the MACD at 6.20 further supports positive sentiment. The stock is also trading above its 20-day EMA of $406.30. Key support levels are near the 50-day SMA, while resistance is less defined given the upward trajectory. Volume has been significantly below average recently, which warrants monitoring as the stock moves higher. The overall chart structure suggests continued upward potential, supported by the prevailing bullish technical indicators.",
    "Elevance Health has a history of exceeding EPS estimates, most recently by 19.97% in the quarter to June 2026, indicating strong operational execution.",
    "Insiders have purchased $5.1 million worth of stock against $3.7 million in sales, signaling a slight buy signal and potential institutional conviction.",
    "Current and next quarter revenue estimates show a year-over-year decline of approximately 2.00%, lagging behind the sector's positive growth.",
    "A majority of analysts maintain Buy or Overweight ratings, with a median price target of $457.00, indicating Wall Street's general optimism.",
    "Elevance Health, Inc. (ELV) is expected to see continued positive performance driven by strong insider selling and consistent earnings beats, with a base case target of $614.96. The company's valuation appears attractive relative to its sector peers, offering a potential upside of 9% to the median analyst target price of $457.00. The primary risks include the current trend of negative revenue growth, which contrasts with sector averages, and potential market reactions to earnings reports despite beats. Upside catalysts could include a reversal in revenue trends or further positive insider selling activity, while downside risks involve persistent revenue contraction or increased competitive pressures within the healthcare insurance market."
   ],
   "lists": {
    "ProTips": [
     "Monitor revenue growth trends closely, as the current negative trajectory contrasts with sector averages and could present a headwind.",
     "Insider net buying activity suggests underlying confidence; consider this as a positive signal for future performance.",
     "Given the consistent earnings beats, investors may find opportunities around earnings release dates, though recent price reactions warrant caution."
    ]
   },
   "catalysts": [
    {
     "type": "Bullish",
     "title": "Consistent Earnings Beats",
     "text": "Elevance Health has a history of exceeding EPS estimates, most recently by 19.97% in the quarter to June 2026, indicating strong operational execution.",
     "source": "Earnings Reports"
    },
    {
     "type": "Bullish",
     "title": "Insider Net Buying Activity",
     "text": "Insiders have purchased $5.1 million worth of stock against $3.7 million in sales, signaling a slight buy signal and potential institutional conviction.",
     "source": "Insider Transactions"
    },
    {
     "type": "Bearish",
     "title": "Negative Revenue Growth Trend",
     "text": "Current and next quarter revenue estimates show a year-over-year decline of approximately 2.00%, lagging behind the sector's positive growth.",
     "source": "Analyst Estimates"
    },
    {
     "type": "Neutral",
     "title": "Analyst Ratings Maintain Positive Stance",
     "text": "A majority of analysts maintain Buy or Overweight ratings, with a median price target of $457.00, indicating Wall Street's general optimism.",
     "source": "Analyst Ratings"
    }
   ]
  },
  {
   "id": "key-statistics",
   "title": "Key Statistics",
   "text": [
    "Elevance Health, Inc. (ELV) trades at a P/E ratio of 18.76, which is below the sector median of 31.9, suggesting a potential valuation discount relative to peers. Its price-to-sales ratio of 0.46 is also lower than the sector average of 3.7. The company's return on equity stands at 11.13%, and its profit margin is 2.47%, with an operating margin of 4.56%. Despite a slight revenue growth of 1.4% compared to the sector median of 8.1%, the company's fundamentals appear sound. The debt-to-equity ratio of 0.69 is within reasonable bounds for the sector. The current valuation metrics suggest that the stock may be undervalued compared to its industry peers, especially considering its consistent earnings beats.",
    "Elevance Health, Inc. (ELV) has demonstrated a strong track record of exceeding earnings expectations. The most recent quarter to June 2026 saw EPS actual of $7.45 against an estimate of $6.21, a surprise of 19.97%, though the stock price declined by 4.48%. Prior quarters also showed positive surprises, including a 16.37% beat in the quarter to March 2026 and a 32% beat in the quarter to December 2025. This consistent outperformance in earnings suggests operational efficiency and effective cost management.",
    "Near-term revenue growth is a concern, with current and next quarter estimates showing a decline, contrasting with the sector's median growth. While insider buying is a positive signal, the recent price reaction to the latest earnings beat warrants attention, suggesting potential market skepticism or broader sector headwinds. The company's valuation, while attractive on a P/E basis, needs to be monitored against its slower revenue growth compared to peers."
   ],
   "tables": [
    {
     "caption": "",
     "columns": [],
     "rows": [
      {
       "label": "Market Cap",
       "cells": [
        "92.00B"
       ]
      },
      {
       "label": "P/E Ratio",
       "cells": [
        "18.76"
       ]
      },
      {
       "label": "EPS (TTM)",
       "cells": [
        "22.61"
       ]
      },
      {
       "label": "Dividend Yield",
       "cells": [
        "1.64%"
       ]
      },
      {
       "label": "52 Week High",
       "cells": [
        "436.24"
       ]
      },
      {
       "label": "52 Week Low",
       "cells": [
        "274.84"
       ]
      }
     ]
    }
   ]
  },
  {
   "id": "technical-indicators",
   "title": "Technical Indicators",
   "text": [
    "Technical Rating Bullish RSI Bullish SMA Cross Bullish Price vs SMA Bullish MACD Bullish Golden Cross in effect with the 50-day SMA ($397.60) above the 200-day SMA ($361.94), price action is firmly bullish above key moving averages."
   ],
   "facts": {
    "RSI": "Bullish",
    "SMA Cross": "Bullish",
    "Price vs SMA": "Bullish",
    "MACD": "Bullish"
   },
   "tables": [
    {
     "caption": "",
     "columns": [],
     "rows": [
      {
       "label": "RSI (14)",
       "cells": [
        "61.77"
       ]
      },
      {
       "label": "MACD",
       "cells": [
        "6.20"
       ]
      },
      {
       "label": "SMA 50",
       "cells": [
        "397.60"
       ]
      },
      {
       "label": "SMA 200",
       "cells": [
        "361.94"
       ]
      }
     ]
    }
   ]
  },
  {
   "id": "correlations",
   "title": "Market Correlations",
   "text": [
    "How this stock moves relative to other assets",
    "Based on 1 year of daily price data. Correlations may vary over different time periods."
   ],
   "facts": {
    "Correlation with S&P 500 (SPY)": "+0.11",
    "Correlation with Nasdaq 100 (QQQ)": "+0.04",
    "Correlation with Bitcoin (BTC)": "+0.03",
    "Correlation with Gold (XAU)": "+0.03"
   }
  },
  {
   "id": "trade-plans",
   "title": "ELV Trade Plans",
   "text": [
    "Specific entry, exit, and risk management levels",
    "Lower risk, wait for pullback",
    "Higher risk, immediate entry",
    "Volatility-Adjusted Stop Loss Calculated based on RSI (61.8) and current market volatility",
    "Consider scaling out: Take 50% profit at Target 1, 30% at Target 2, let 20% run to Target 3"
   ],
   "facts": {
    "TARGET 1": "$431.33",
    "TARGET 2": "$451.87",
    "TARGET 3": "$472.40",
    "STOP LOSS": "$398.46"
   }
  },
  {
   "id": "seasonality",
   "title": "Seasonal Patterns",
   "text": [
    "Historical monthly performance trends",
    "Based on 3 years of historical monthly returns"
   ],
   "facts": {
    "Average Jan return": "+2.07%",
    "Average Feb return": "-1.18%",
    "Average Mar return": "+0.62%",
    "Average Apr return": "+6.81%",
    "Average May return": "+1.39%",
    "Average Jun return": "-1.13%",
    "Average Jul return": "-2.38%",
    "Average Aug return": "+1.63%",
    "Average Sep return": "-2.22%",
    "Average Oct return": "+3.13%",
    "Average Nov return": "+6.74%",
    "Average Dec return": "-0.21%"
   }
  },
  {
   "id": "risk",
   "title": "Risk & Volatility",
   "facts": {
    "Daily Volatility": "1.68%"
   },
   "lists": {
    "Risk considerations": [
     "Monitor position sizing based on current volatility levels",
     "Consider stop-loss placement beyond recent price range",
     "Diversification helps mitigate single-stock risk exposure"
    ]
   }
  },
  {
   "id": "growth",
   "title": "Growth of $10,000",
   "text": [
    "A $10,000 investment in ELV in September 2016 would be worth about $34,119 today, compared with about $35,344 for the same investment in the S&P 500 benchmark."
   ]
  },
  {
   "id": "monte-carlo",
   "title": "Monte Carlo Projection (10yr)",
   "text": [
    "CleaRank's 10-year Monte Carlo simulation projects that a $10,000 investment in ELV today could grow to about $26,070 by 2036 in the base case, with a bull case near $92,933 and a bear case around $7,313. Projections are statistical simulations, not guarantees."
   ]
  },
  {
   "id": "price-prediction",
   "title": "ELV Stock Price Prediction: 2030",
   "text": [
    "CleaRank's simulation projects a price near $615 for ELV by 2030 in the base case, from $419 today (1.5x over 4 years). The downside path ends near $275. These are outcomes of a Monte Carlo simulation run on ELV's historical return distribution, not price targets, and they assume no dividends are reinvested.",
    "Method: 10,000 simulated price paths using ELV's historical volatility and drift, re-run daily. The base case is the median path; the two outer columns are the 10th and 90th percentile outcomes, which widen with time because uncertainty compounds. Simulations are not guarantees, and past volatility does not predict future returns. This is analysis, not investment advice."
   ],
   "tables": [
    {
     "caption": "ELV simulated price paths by year",
     "columns": [
      "Year",
      "Downside (10th pct)",
      "Base case",
      "Upside (90th pct)"
     ],
     "rows": [
      {
       "label": "2027",
       "cells": [
        "$309",
        "$461",
        "$690"
       ]
      },
      {
       "label": "2028",
       "cells": [
        "$288",
        "$508",
        "$896"
       ]
      },
      {
       "label": "2029",
       "cells": [
        "$279",
        "$559",
        "$1,121"
       ]
      },
      {
       "label": "2030",
       "cells": [
        "$275",
        "$615",
        "$1,374"
       ]
      },
      {
       "label": "2031",
       "cells": [
        "$275",
        "$677",
        "$1,663"
       ]
      },
      {
       "label": "2032",
       "cells": [
        "$278",
        "$745",
        "$1,994"
       ]
      },
      {
       "label": "2033",
       "cells": [
        "$283",
        "$820",
        "$2,374"
       ]
      },
      {
       "label": "2034",
       "cells": [
        "$289",
        "$902",
        "$2,812"
       ]
      },
      {
       "label": "2035",
       "cells": [
        "$297",
        "$993",
        "$3,316"
       ]
      },
      {
       "label": "2036",
       "cells": [
        "$307",
        "$1,093",
        "$3,895"
       ]
      }
     ]
    }
   ]
  },
  {
   "id": "people-also-watch",
   "title": "People Also Watch",
   "links": [
    {
     "text": "BNTX BioNTech SE NASDAQ $96.69 -2.20%",
     "url": "https://clearank.com/stock/bntx-stock-analysis/"
    },
    {
     "text": "DHR Danaher Corp. NYSE $209.36 +3.01%",
     "url": "https://clearank.com/stock/dhr-stock-analysis/"
    },
    {
     "text": "CNC Centene Corp. NYSE $67.66 -2.52%",
     "url": "https://clearank.com/stock/centene-cnc/"
    },
    {
     "text": "OFIX Orthofix Medical Inc. NASDAQ $9.09 -0.22%",
     "url": "https://clearank.com/stock/ofix-stock-analysis/"
    },
    {
     "text": "DXCM DexCom Inc. NASDAQ $86.45 +2.09%",
     "url": "https://clearank.com/stock/dxcm-stock-analysis/"
    },
    {
     "text": "MCK McKesson Corporation NYSE $899.56 -1.25%",
     "url": "https://clearank.com/stock/mck-stock-analysis/"
    },
    {
     "text": "BDX Becton, Dickinson and Company NYSE $185.92 +1.65%",
     "url": "https://clearank.com/stock/bdx-stock-analysis/"
    },
    {
     "text": "CRNX Crinetics Pharmaceuticals, Inc. NASDAQ $84.95 +0.00%",
     "url": "https://clearank.com/stock/crinetics-pharmaceuticals-crnx/"
    }
   ]
  },
  {
   "id": "related-comparisons",
   "title": "Compare ELV",
   "links": [
    {
     "text": "ELV vs HUM Comparison Head-to-head analysis →",
     "url": "https://clearank.com/compare/elv-vs-hum/"
    },
    {
     "text": "FITB vs HBAN Comparison Head-to-head analysis →",
     "url": "https://clearank.com/compare/fitb-vs-hban/"
    },
    {
     "text": "COST vs WMT Comparison Head-to-head analysis →",
     "url": "https://clearank.com/compare/cost-vs-wmt/"
    }
   ]
  },
  {
   "id": "insider-trading",
   "title": "ELV Insider Trading Analysis",
   "facts": {
    "Bought": "$5.1M",
    "Sold": "$3.7M",
    "Insiders": "22",
    "Avg Transaction": "$795.0K"
   },
   "tables": [
    {
     "caption": "Recent insider transactions in ELV",
     "columns": [
      "Date",
      "Insider",
      "Type",
      "Shares",
      "Value"
     ],
     "rows": [
      {
       "label": "Mar 22, 2021",
       "cells": [
        "HAYTAIAN PETER D Officer",
        "Sell",
        "59.5K",
        "$20.8M"
       ]
      },
      {
       "label": "May 24, 2021",
       "cells": [
        "GALLINA JOHN E Chief Financial Officer",
        "Sell",
        "46.4K",
        "$18.3M"
       ]
      },
      {
       "label": "Jul 22, 2024",
       "cells": [
        "BOUDREAUX GAIL A KOZIARA Chief Executive Officer",
        "Sell",
        "34.0K",
        "$17.0M"
       ]
      },
      {
       "label": "Apr 24, 2024",
       "cells": [
        "NORWOOD FELICIA F. Officer",
        "Sell",
        "20.3K",
        "$10.8M"
       ]
      },
      {
       "label": "Mar 4, 2024",
       "cells": [
        "HAYTAIAN PETER D Officer",
        "Sell",
        "21.1K",
        "$10.6M"
       ]
      },
      {
       "label": "Mar 10, 2022",
       "cells": [
        "HAYTAIAN PETER D Officer",
        "Sell",
        "17.7K",
        "$8.2M"
       ]
      },
      {
       "label": "Mar 24, 2023",
       "cells": [
        "MCCARTHY GLORIA M Officer",
        "Sell",
        "15.1K",
        "$6.7M"
       ]
      },
      {
       "label": "Apr 30, 2020",
       "cells": [
        "ZIELINSKI THOMAS C General Counsel",
        "Sell",
        "19.3K",
        "$5.4M"
       ]
      },
      {
       "label": "May 15, 2020",
       "cells": [
        "MCCARTHY GLORIA M Officer",
        "Sell",
        "18.3K",
        "$5.0M"
       ]
      },
      {
       "label": "Apr 16, 2020",
       "cells": [
        "MCCARTHY GLORIA M Officer",
        "Sell",
        "16.9K",
        "$4.6M"
       ]
      }
     ]
    }
   ],
   "links": [
    {
     "text": "SEC Form 4",
     "url": "https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&company=Elevance+Health%2C+Inc.&type=4&dateb=&owner=include&count=40&search_text=&action=getcompany"
    }
   ]
  },
  {
   "id": "faq",
   "title": "Frequently Asked Questions"
  }
 ],
 "faq": [
  {
   "question": "What is Elevance Health's stock price forecast for 2030?",
   "answer": "Elevance Health's stock price forecast for 2030, based on Monte Carlo simulations, projects a base case of $614.96, with a downside scenario of $275.24 and an upside scenario of $1373.98. These figures represent statistical outcomes, not guaranteed price targets."
  },
  {
   "question": "Is Elevance Health stock a buy right now?",
   "answer": "Elevance Health (ELV) is currently rated as a Buy with a consensus score of 70 out of 100. The stock is trading above key moving averages, showing bullish momentum, and insiders are net sellers, signaling institutional confidence."
  },
  {
   "question": "What is the consensus rating for Elevance Health?",
   "answer": "The consensus rating for Elevance Health is Buy, supported by a consensus score of 70 out of 100. Wall Street analysts have a median price target of $457.00, implying a 9% upside from the current price."
  },
  {
   "question": "How has Elevance Health performed in recent earnings reports?",
   "answer": "Elevance Health has consistently beaten earnings estimates. The latest quarter to June 2026 showed a 19.97% EPS surprise, following a 16.37% beat in the prior quarter. This pattern of earnings outperformance indicates strong operational execution."
  },
  {
   "question": "What are the key technical indicators for Elevance Health?",
   "answer": "Elevance Health is trading above its 50-day and 200-day moving averages ($397.60 and $361.94), with bullish momentum indicated by its RSI at 61.8 and a positive MACD. The stock is also above its 20-day EMA, suggesting a positive short-to-medium term trend."
  },
  {
   "question": "Are there any significant insider transactions for Elevance Health?",
   "answer": "Yes, insiders at Elevance Health have been net buyers, with total purchases of $5.1 million compared to $3.7 million in sales in recent filings. This activity, resulting in a 1.37 buy-sell ratio, suggests a slight buy signal and insider confidence in the company's prospects."
  },
  {
   "question": "How does Elevance Health compare to its sector averages?",
   "answer": "Elevance Health's P/E ratio of 18.76 is below the sector median of 31.9, and its price-to-sales ratio of 0.46 is also lower than the sector average of 3.7. However, its revenue growth of 1.4% lags behind the sector median of 8.1%."
  }
 ],
 "related": {
  "peopleAlsoWatch": [
   {
    "ticker": "BNTX",
    "name": "BioNTech SE NASDAQ",
    "price": "$96.69",
    "change": "-2.20%",
    "url": "https://clearank.com/stock/bntx-stock-analysis/"
   },
   {
    "ticker": "DHR",
    "name": "Danaher Corp. NYSE",
    "price": "$209.36",
    "change": "+3.01%",
    "url": "https://clearank.com/stock/dhr-stock-analysis/"
   },
   {
    "ticker": "CNC",
    "name": "Centene Corp. NYSE",
    "price": "$67.66",
    "change": "-2.52%",
    "url": "https://clearank.com/stock/centene-cnc/"
   },
   {
    "ticker": "OFIX",
    "name": "Orthofix Medical Inc. NASDAQ",
    "price": "$9.09",
    "change": "-0.22%",
    "url": "https://clearank.com/stock/ofix-stock-analysis/"
   },
   {
    "ticker": "DXCM",
    "name": "DexCom Inc. NASDAQ",
    "price": "$86.45",
    "change": "+2.09%",
    "url": "https://clearank.com/stock/dxcm-stock-analysis/"
   },
   {
    "ticker": "MCK",
    "name": "McKesson Corporation NYSE",
    "price": "$899.56",
    "change": "-1.25%",
    "url": "https://clearank.com/stock/mck-stock-analysis/"
   },
   {
    "ticker": "BDX",
    "name": "Becton, Dickinson and Company NYSE",
    "price": "$185.92",
    "change": "+1.65%",
    "url": "https://clearank.com/stock/bdx-stock-analysis/"
   },
   {
    "ticker": "CRNX",
    "name": "Crinetics Pharmaceuticals, Inc. NASDAQ",
    "price": "$84.95",
    "change": "+0.00%",
    "url": "https://clearank.com/stock/crinetics-pharmaceuticals-crnx/"
   }
  ],
  "comparisons": [
   {
    "ticker": "ELV vs HUM Comparison",
    "name": "",
    "url": "https://clearank.com/compare/elv-vs-hum/"
   },
   {
    "ticker": "FITB vs HBAN Comparison",
    "name": "",
    "url": "https://clearank.com/compare/fitb-vs-hban/"
   },
   {
    "ticker": "COST vs WMT Comparison",
    "name": "",
    "url": "https://clearank.com/compare/cost-vs-wmt/"
   }
  ],
  "sectorHub": {
   "text": "Browse all Healthcare →",
   "url": "https://clearank.com/sector/healthcare/"
  },
  "Newly Tracked": [
   {
    "ticker": "ILMN",
    "text": "Illumina Inc.",
    "url": "https://clearank.com/stock/ilmn-stock-analysis/"
   },
   {
    "ticker": "FIS",
    "text": "Fidelity National Information Services, Inc.",
    "url": "https://clearank.com/stock/fis-stock-analysis/"
   },
   {
    "ticker": "EXC",
    "text": "Exelon Corp.",
    "url": "https://clearank.com/stock/exc-stock-analysis/"
   },
   {
    "ticker": "GWW",
    "text": "W.W. Grainger Inc.",
    "url": "https://clearank.com/stock/gww-stock-analysis/"
   },
   {
    "ticker": "CDE",
    "text": "Coeur Mining Inc.",
    "url": "https://clearank.com/stock/cde-stock-analysis/"
   }
  ],
  "Top Movers (24h)": [
   {
    "ticker": "FPS",
    "text": "↑ 9.50%",
    "url": "https://clearank.com/stock/fps-stock-analysis/"
   },
   {
    "ticker": "QRVO",
    "text": "↑ 9.34%",
    "url": "https://clearank.com/stock/qorvo-qrvo/"
   },
   {
    "ticker": "RAY/USD",
    "text": "↓ 9.20%",
    "url": "https://clearank.com/crypto/raydium-ray-usd/"
   },
   {
    "ticker": "EGLD/USD",
    "text": "↓ 9.14%",
    "url": "https://clearank.com/crypto/egld-usd-crypto-analysis/"
   },
   {
    "ticker": "SBET",
    "text": "↓ 8.96%",
    "url": "https://clearank.com/stock/sharplink-sbet/"
   }
  ],
  "Also in Healthcare": [
   {
    "ticker": "CI",
    "text": "The Cigna Group",
    "url": "https://clearank.com/stock/cigna-group-ci/"
   },
   {
    "ticker": "CNC",
    "text": "Centene Corporation",
    "url": "https://clearank.com/stock/centene-cnc/"
   },
   {
    "ticker": "CVS",
    "text": "CVS Health",
    "url": "https://clearank.com/stock/cvs-health-cvs/"
   },
   {
    "ticker": "HUM",
    "text": "Humana Inc",
    "url": "https://clearank.com/stock/hum-stock-analysis/"
   },
   {
    "ticker": "MOH",
    "text": "Molina Healthcare Inc.",
    "url": "https://clearank.com/stock/moh-stock-analysis/"
   }
  ]
 },
 "schema": [
  {
   "@context": "https://schema.org",
   "@graph": [
    {
     "@type": "Place",
     "@id": "https://clearank.com/#place",
     "address": {
      "@type": "PostalAddress",
      "streetAddress": "Beni Berman 2",
      "addressLocality": "Netanya",
      "addressRegion": "Center",
      "postalCode": "4249330",
      "addressCountry": "IL"
     }
    },
    {
     "@type": "Organization",
     "@id": "https://clearank.com/#organization",
     "name": "CleaRank",
     "alternateName": "CleaRank Financial AI",
     "url": "https://clearank.com",
     "description": "CleaRank is where retail traders research a trade and practice it before risking money. Its research arm, CleaRank Financial AI, publishes daily analysis, trade plans and 10-year projections for more than 1,000 stocks, ETFs, cryptocurrencies, forex pairs and commodities; each page is built from licensed market data, carries the date it was last updated and is reviewed under CleaRank's published editorial code. The CLEAR™ Score rates online brokers and prop firms on regulation, fees, platform reliability and verified trader experience. The research is free; CleaRank is paid for by subscriptions to its trading workbench (Pro $29 a month, Ultra $59 a month), which combines a live trading simulator, a trade journal that imports from broker history, an AI coach grounded in the trader's own trades, a portfolio generator, visualizer and backtester, a prop-firm challenge auditor and 22 trading calculators and scanners. Some free content contains partner links, which are disclosed and do not affect ratings.",
     "slogan": "Clear data. Honest analysis.",
     "logo": {
      "@type": "ImageObject",
      "@id": "https://clearank.com/#logo",
      "url": "https://clearank.com/media/uploads/2025/02/CleaRank-Logo-e1738621466340.jpg",
      "contentUrl": "https://clearank.com/media/uploads/2025/02/CleaRank-Logo-e1738621466340.jpg",
      "caption": "CleaRank",
      "inLanguage": "en-US",
      "width": "336",
      "height": "153"
     },
     "image": {
      "@id": "https://clearank.com/#logo"
     },
     "sameAs": [
      "https://x.com/CleaRank",
      "https://www.linkedin.com/company/clearank/",
      "https://www.youtube.com/@CleaRank",
      "https://t.me/clearank"
     ],
     "email": "info@clearank.com",
     "contactPoint": [
      {
       "@type": "ContactPoint",
       "contactType": "customer support",
       "email": "info@clearank.com",
       "url": "https://clearank.com/contact/",
       "availableLanguage": "en"
      }
     ],
     "address": {
      "@type": "PostalAddress",
      "streetAddress": "Beni Berman 2",
      "addressLocality": "Netanya",
      "addressRegion": "Center",
      "postalCode": "4249330",
      "addressCountry": "IL"
     },
     "location": {
      "@id": "https://clearank.com/#place"
     },
     "knowsAbout": [
      "stock analysis",
      "ETF analysis",
      "cryptocurrency analysis",
      "forex trading",
      "trading simulation",
      "trade journaling",
      "position sizing",
      "risk management",
      "prop firm challenges",
      "online broker regulation"
     ],
     "publishingPrinciples": "https://clearank.com/editorial-code/",
     "ethicsPolicy": "https://clearank.com/editorial-code/",
     "ownershipFundingInfo": "https://clearank.com/about-us/",
     "owns": {
      "@id": "https://clearank.com/#app"
     },
     "founder": {
      "@id": "https://clearank.com/writer/shaundavidb/#person"
     }
    },
    {
     "@type": "WebSite",
     "@id": "https://clearank.com/#website",
     "url": "https://clearank.com",
     "name": "CleaRank",
     "publisher": {
      "@id": "https://clearank.com/#organization"
     },
     "inLanguage": "en-US"
    },
    {
     "@type": "ImageObject",
     "@id": "https://clearank.com/wp-content/uploads/2026/07/ELV-elevance-health-analysis-2026-07.png",
     "url": "https://clearank.com/wp-content/uploads/2026/07/ELV-elevance-health-analysis-2026-07.png",
     "width": "1280",
     "height": "720",
     "caption": "Elevance Health (ELV) stock price analysis chart for July 2026",
     "inLanguage": "en-US"
    },
    {
     "@type": "BreadcrumbList",
     "@id": "https://clearank.com/stock/elv-stock-analysis/#breadcrumb",
     "itemListElement": [
      {
       "@type": "ListItem",
       "position": "1",
       "item": {
        "@id": "https://clearank.com",
        "name": "Home"
       }
      },
      {
       "@type": "ListItem",
       "position": "2",
       "item": {
        "@id": "https://clearank.com/stock/elv-stock-analysis/",
        "name": "Elevance Health (ELV) Stock Analysis"
       }
      }
     ]
    },
    {
     "@type": "WebPage",
     "@id": "https://clearank.com/stock/elv-stock-analysis/#webpage",
     "url": "https://clearank.com/stock/elv-stock-analysis/",
     "name": "Elevance Health (ELV) Stock Forecast & Price Target (2026)",
     "datePublished": "2026-07-10T09:21:03+00:00",
     "dateModified": "2026-09-15T15:51:58+00:00",
     "isPartOf": {
      "@id": "https://clearank.com/#website"
     },
     "primaryImageOfPage": {
      "@id": "https://clearank.com/wp-content/uploads/2026/07/ELV-elevance-health-analysis-2026-07.png"
     },
     "inLanguage": "en-US",
     "breadcrumb": {
      "@id": "https://clearank.com/stock/elv-stock-analysis/#breadcrumb"
     },
     "reviewedBy": {
      "@id": "https://clearank.com/writer/shaundavidb/#person"
     }
    },
    {
     "@type": "Person",
     "@id": "https://clearank.com/writer/shaundavidb/#person",
     "name": "Shaun David",
     "jobTitle": "Co-Founder",
     "url": "https://clearank.com/writer/shaundavidb/",
     "image": "https://clearank.com/media/uploads/2025/01/Shaun-David-Author-Image-.jpeg",
     "sameAs": [
      "https://www.linkedin.com/in/shaun-david-697b5817a/"
     ],
     "worksFor": {
      "@id": "https://clearank.com/#organization"
     }
    },
    {
     "@type": "Article",
     "@id": "https://clearank.com/stock/elv-stock-analysis/#richSnippet",
     "headline": "Elevance Health (ELV) Stock Forecast & Price Target (2026)",
     "name": "Elevance Health (ELV) Stock Forecast & Price Target (2026)",
     "description": "Elevance Health, Inc. (ELV) stock: Healthcare, Healthcare Plans. $92.0B market cap. AI rating, technicals, 2030 forecast and trade plans.",
     "datePublished": "2026-07-10T09:21:03+00:00",
     "dateModified": "2026-09-15T15:51:58+00:00",
     "author": {
      "@id": "https://clearank.com/#organization"
     },
     "publisher": {
      "@id": "https://clearank.com/#organization"
     },
     "publishingPrinciples": "https://clearank.com/editorial-code/",
     "about": {
      "@type": "Corporation",
      "name": "Elevance Health, Inc.",
      "identifier": [
       {
        "@type": "PropertyValue",
        "propertyID": "tickerSymbol",
        "value": "ELV"
       },
       {
        "@type": "PropertyValue",
        "propertyID": "exchange",
        "value": "NYSE"
       }
      ],
      "description": "Elevance Health, Inc. is a U.S. health benefits and health services company headquartered in Indianapolis, Indiana. It provides a broad range of health insurance products and related services for individuals, employers, and government-sponsored programs, with offerings that include commercial medica",
      "tickerSymbol": "ELV",
      "sameAs": "https://www.elevancehealth.com"
     },
     "isPartOf": {
      "@id": "https://clearank.com/stock/elv-stock-analysis/#webpage"
     },
     "image": {
      "@id": "https://clearank.com/wp-content/uploads/2026/07/ELV-elevance-health-analysis-2026-07.png"
     },
     "inLanguage": "en-US",
     "mainEntityOfPage": {
      "@id": "https://clearank.com/stock/elv-stock-analysis/#webpage"
     }
    }
   ]
  },
  {
   "@context": "https://schema.org",
   "@type": "FAQPage",
   "mainEntity": [
    {
     "@type": "Question",
     "name": "What is Elevance Health's stock price forecast for 2030?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "Elevance Health's stock price forecast for 2030, based on Monte Carlo simulations, projects a base case of $614.96, with a downside scenario of $275.24 and an upside scenario of $1373.98. These figures represent statistical outcomes, not guaranteed price targets."
     }
    },
    {
     "@type": "Question",
     "name": "Is Elevance Health stock a buy right now?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "Elevance Health (ELV) is currently rated as a Buy with a consensus score of 70 out of 100. The stock is trading above key moving averages, showing bullish momentum, and insiders have been net buyers, signaling institutional confidence."
     }
    },
    {
     "@type": "Question",
     "name": "What is the consensus rating for Elevance Health?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "The consensus rating for Elevance Health is Buy, supported by a consensus score of 70 out of 100. Wall Street analysts have a median price target of $457.00, implying a 9% upside from the current price."
     }
    },
    {
     "@type": "Question",
     "name": "How has Elevance Health performed in recent earnings reports?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "Elevance Health has consistently beaten earnings estimates. The latest quarter to June 2026 showed a 19.97% EPS surprise, following a 16.37% beat in the prior quarter. This pattern of earnings outperformance indicates strong operational execution."
     }
    },
    {
     "@type": "Question",
     "name": "What are the key technical indicators for Elevance Health?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "Elevance Health is trading above its 50-day and 200-day SMAs, with bullish momentum indicated by its RSI of 61.77 and a positive MACD. The stock is also above its 20-day EMA, suggesting a positive short-to-medium term trend."
     }
    },
    {
     "@type": "Question",
     "name": "Are there any significant insider transactions for Elevance Health?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "Yes, insiders at Elevance Health have been net buyers, with total purchases of $5.1 million compared to $3.7 million in sales across 44 transactions. This activity, resulting in a 1.37 buy-sell ratio, suggests a slight buy signal and insider confidence in the company's prospects."
     }
    },
    {
     "@type": "Question",
     "name": "How does Elevance Health compare to its sector averages?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "Elevance Health's P/E ratio of 18.76 is below the sector median of 31.9, and its price-to-sales ratio of 0.46 is also lower than the sector average of 3.7. However, its revenue growth of 1.4% lags behind the sector median of 8.1%."
     }
    }
   ]
  }
 ]
}